18 December 2023
18 December 2023
Following US and UK approvals, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended conditional approval for Casgevy, with a decision expected in Q1 2024.
Reneo’s mavodelpar failed to meet its endpoints in the Phase III trial in primary mitochondrial myopathies, a rare genetic disorder.
This is the second FDA approval for MSD’s HIF-2α inhibitor following a 2021 approval to treat von Hippel-Lindau disease.
The development is based on positive findings from the Phase III ADVANCE-CIDP 1 trial of Hyqvia in adult CIDP patients.
Biocytogen is entitled to receive an upfront payment from Ona linked to the option exercise.
The application is based on data from the Phase III RESPONSE and ENHANCE clinical trials.
The approval is based on data from the Phase III EV-302 clinical trial of Padcev plus Merck (MSD)’s Keytruda.
The Inflation Reduction Act targets annual savings of $25m by 2031 by requiring drugmakers to negotiate the prices of selected expensive drugs.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
A comprehensive outlook for the leading players across the TMT industry, based on the key themes set to transform the industry landscape over the next two years. You will not find a better guide to technology in 2024.
Give your business an edge with our leading industry insights.
